Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in receptor binding radiopharmaceuticals.

P Angelberger1

  • 1Department of Chemical Engineering, Osterreichisches Forschungszentrum Seibersdorf.

Wiener Klinische Wochenschrift
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Imaging of highly malignant osteosarcoma with iodine-123-vascular endothelial growth factor.

Oncology·2012
Same author

Improved quality of life in patients treated with Peptide radionuclides.

World journal of nuclear medicine·2011
Same author

Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival.

Nuklearmedizin. Nuclear medicine·2008
Same author

Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2004
Same author

Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy.

Annals of oncology : official journal of the European Society for Medical Oncology·2003
Same author

Experience with indium-111 and yttrium-90-labeled somatostatin analogs.

Current pharmaceutical design·2002
Same journal

[Vaccination of immunocompromised individuals: Expert opinion - update 2026].

Wiener klinische Wochenschrift·2026
Same journal

Systematic review of clinical evidence for Kneipp medicine.

Wiener klinische Wochenschrift·2026
Same journal

Pelvic resections in primary sarcomas : Surgical outcomes and survival analysis of 75 patients.

Wiener klinische Wochenschrift·2026
Same journal

Jungmediziner*innen am Start: 11. Workshop für den medizinischen Nachwuchs.

Wiener klinische Wochenschrift·2026
Same journal

Stellungnahme der ÖGP zur geplanten Gesetzesnovelle zum Nichtraucherschutzgesetz.

Wiener klinische Wochenschrift·2026
Same journal

MUW researcher of the month: Dr. Moritz Schaefer.

Wiener klinische Wochenschrift·2026
See all related articles

Researchers developed radioligands for studying receptor-ligand interactions. These include Tc99m-Neo-Galacto-Albumin for Hepatic Binding Protein and I-123 labeled compounds for Dopamine receptors, aiding atherosclerosis and neurological research.

Area of Science:

  • Radiochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Ligand-receptor interactions are crucial in biological processes.
  • Radionuclide-labeled ligands with high purity and specific activity are essential for studying these interactions.
  • Previous research has focused on developing such radioligands for various biological targets.

Purpose of the Study:

  • To describe the radiochemical development of novel radioligands at the Austrian Research Centre Seibersdorf.
  • To synthesize and characterize radiolabeled compounds for specific receptor targets.
  • To evaluate the potential of these radioligands in biological and medical research.

Main Methods:

  • Radiochemical synthesis of Tc99m-Neo-Galacto-Albumin for Hepatic Binding Protein receptor.

Related Experiment Videos

  • Radiolabeling of Low Density Lipoprotein (LDL) with I-123, Tc99m, and In-111 for LDL-receptors.
  • Stereoisomer separation and radiolabeling of a pyrrolidine-methyl-benzamide derivative with I-123.
  • Radiolabeling of a benzazepine derivative with I-123.

    • Main Results:

    • Successful preparation of Tc99m-Neo-Galacto-Albumin.
    • Development of I-123, Tc99m, and In-111 labeled LDL for studying LDL-receptor interactions and atherosclerosis.
    • Isolation of an active stereoisomer of a pyrrolidine-methyl-benzamide derivative, labeled with I-123, showing specific uptake in Dopamine D-2 receptor-rich brain tissue.
    • Synthesis of an I-123 labeled benzazepine derivative as a potential ligand for Dopamine D-1 receptors.

    Conclusions:

    • The developed radioligands are valuable tools for investigating specific receptor-ligand interactions.
    • These radioligands have potential applications in diagnosing and understanding diseases like atherosclerosis and neurological disorders.
    • The radiochemical methods employed enable the production of high-quality radiotracers for preclinical and clinical research.